share_log

Redhill Biopharma | UPLOAD: Others

Redhill Biopharma | UPLOAD: Others

Redhill Biopharma | UPLOAD:其他
SEC announcement ·  02/14 12:59
Moomoo AI 已提取核心訊息
RedHill Biopharma Ltd., a biopharmaceutical company, received a notification from the United States Securities and Exchange Commission (SEC) on February 14, 2024, regarding its Registration Statement on Form F-1, which was filed on February 9, 2024. The SEC informed the company that it has not reviewed and will not review the registration statement. The SEC's communication reminded RedHill Biopharma of its responsibility for the accuracy and adequacy of the disclosures in the registration statement. The SEC also pointed out Rules 460 and 461, which pertain to requests for acceleration of the registration process. RedHill Biopharma's CEO, Dror Ben-Asher, was directed to contact Tim Buchmiller at the SEC with any further questions.
RedHill Biopharma Ltd., a biopharmaceutical company, received a notification from the United States Securities and Exchange Commission (SEC) on February 14, 2024, regarding its Registration Statement on Form F-1, which was filed on February 9, 2024. The SEC informed the company that it has not reviewed and will not review the registration statement. The SEC's communication reminded RedHill Biopharma of its responsibility for the accuracy and adequacy of the disclosures in the registration statement. The SEC also pointed out Rules 460 and 461, which pertain to requests for acceleration of the registration process. RedHill Biopharma's CEO, Dror Ben-Asher, was directed to contact Tim Buchmiller at the SEC with any further questions.
生物製藥公司RedHill Biopharma Ltd. 於2024年2月14日收到美國證券交易委員會(SEC)關於其於2024年2月9日提交的F-1表格註冊聲明的通知。美國證券交易委員會告知該公司,它尚未審查註冊聲明,也不會審查註冊聲明。美國證券交易委員會的來文提醒RedHill Biopharma,它對註冊聲明中披露的準確性和充分性負責。美國證券交易委員會還指出了與加快註冊程序的請求有關的第460和461條。如果有任何其他問題,紅山生物製藥首席執行官德羅爾·本·阿舍爾被指示聯繫美國證券交易委員會的蒂姆·布赫米勒。
生物製藥公司RedHill Biopharma Ltd. 於2024年2月14日收到美國證券交易委員會(SEC)關於其於2024年2月9日提交的F-1表格註冊聲明的通知。美國證券交易委員會告知該公司,它尚未審查註冊聲明,也不會審查註冊聲明。美國證券交易委員會的來文提醒RedHill Biopharma,它對註冊聲明中披露的準確性和充分性負責。美國證券交易委員會還指出了與加快註冊程序的請求有關的第460和461條。如果有任何其他問題,紅山生物製藥首席執行官德羅爾·本·阿舍爾被指示聯繫美國證券交易委員會的蒂姆·布赫米勒。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息